US, Korea FTA Talks To Improve Pro-Innovation Pricing System
Executive Summary
The US and South Korea's agreement to modify Korea's drug pricing system for innovative drugs raises concerns over an increased price burden for global drugs in the country.
You may also be interested in...
Jitters Over Innovative Drug Pricing System Intensify In Korea As FTA Revision Deadline Nears
Concerns are brewing in South Korea as a deadline to revise the global innovative drug pricing system nears as part of the revised FTA with the US. One lawmaker has asked the government to cautiously negotiate with the US over any revisions to protect the domestic pharma industry and financial status of the national health insurance scheme.
Korea Seeks Fast Tracks For Innovative And Public Health Crisis Drugs
Korean pharma industry welcomes a bill that aims to establish fast-track review and approval system for innovative drugs and medicines used in public health crises.
Korea's Reimbursement Steps Spark Drug Price Cut Concerns
In its first announcement of major health care measures since the Moon Jae-in administration took charge, South Korea unveils steps to hike its national health insurance coverage ratio to levels in advanced countries, raising concerns that this might lead to sharp drug price cuts.